EE380 Cost-Effectiveness Analysis of Erlotinib Plus Bevacizumab As First-Line Therapy for Advanced EGFR Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer in Japan
Abstract
Authors
S. Yoshioka W. Chen T. Maeda K. Morimoto K. Moriwaki K. Shimozuma